Titan Pharmaceuticals, Inc. (NASDAQ: TTNP), based in South San Francisco, CA, is a commercial stage company developing proprietary therapeutics with its ProNeura™ long-term, continuous drug delivery technology.  The company’s lead product is Probuphine®, a novel and long-acting formulation of buprenorphine for the long-term maintenance treatment of opioid dependence.

 

The company recently announced the pricing of an underwritten public offering with expected total gross proceeds of $9,500,000, before deducting underwriting discounts, commissions and other offering expenses payable by the Company.

 

Before this on August 14th, the company reported financial results for the second quarter ended June 30, 2018 and provided an update on its business. The company is making significant progress in transitioning to a commercial company. Moving forward, it will be focusing on four key market segments: high Probuphine-prescribing physicians with long-term recovery-oriented treatment programs; residential facilities that utilize medication-assisted treatment; academic institutions with addiction residency and fellowships programs; and the criminal justice system.

 

Titan’s Executive Chairman, Dr. Marc Rubin, commented, “We are encouraged by the early progress we have made in the relaunch of Probuphine in the U.S., and continue to work closely with Molteni and the team of addiction medicine experts that we have assembled to help position Probuphine for global success.”

 

More recently on September 4th, the company announced the initiation of a pilot program in collaboration with the Nevada Center for Behavioral Health (NCBH) to evaluate a medication-assisted treatment (MAT) program utilizing Probuphine (buprenorphine) implant for Opioid Use Disorder (OUD) patients within the State of Nevada criminal justice system. The management is looking forward to seeing the results of this pilot MAT program for OUD patients, both inside and, ultimately, outside of Nevada’s prison and jail systems.

______________________________________________________________________

Our members have booked up to 800% with our recent (2018) NASDAQ and NYSE small cap alerts. We will be initiating coverage on another exciting small cap security mid-week this week (10/14/18). View our recent picks, track record and sign up for our real time mobile/text alerts here – https://tradersnewssource.com/traders-news-source-new-members/

______________________________________________________________________

Driven by its favorable fundamentals, Titan has become a momentum stock in the recent past. The company is continuously progressing towards commercialization stage following reacquisition of Probuphine® rights in the U.S.

 

Key & unique differentiating factor of the company:

Lead product, Probuphine, is an implant formulation of buprenorphine for the long-term maintenance treatment of opioid use disorder (OUD)

• Approved in U.S. and Canada, under regulatory review in EU
• An important therapeutic option to fight the growing opioid addiction pandemic

ProNeura™ platform technology provides continuous delivery, maintaining a stable blood level of selected drugs for the treatment of addiction and other disease categories

• Pain, Parkinson’s disease, malaria, diabetes, thyroid disease

 

 

 The company is aggressively evaluating the market for opioid use disorder and start laying the necessary groundwork and strategies to position Probuphine for success. The market is bullish about the significant and growing market for Probuphine, which has the potential to address critical unmet needs in this global epidemic.

 

The market cap of just $5.4 million and share now ruling at $0.20, can move to a level of about $1.5 -$2 in the next six to twelve months. Research firms are positive about the performance of Titan Pharmaceuticals, Inc. (TTNP) with most of them predicting a $1.5 – $2 per share price target over the near to medium term. Per www.marketbeat.com, Their average twelve-month price target is $2.00, suggesting that the stock has a possible upside of 900.00%. The high price target for TTNP is $2.00, and the low-price target for TTNP is $2.00. Considering all this, the company is in an extremely favorable risk-reward position, and value investors should consider exposure in this sector as the backdrop remains favorable.

 

Description & about the Company: Titan Pharmaceuticals, Inc. (NASDAQ: TTNP), based in South San Francisco, CA, is developing proprietary therapeutics primarily for the treatment of select chronic diseases.

The company’s lead product is Probuphine®, a novel and long-acting formulation of buprenorphine for the long-term maintenance treatment of opioid dependence. Probuphine employs Titan’s proprietary drug delivery system ProNeura™, which is capable of delivering sustained, consistent levels of medication for three months or longer.

Approved by the FDA in May 2016, Probuphine is the first and only commercialized treatment of opioid dependence to provide continuous, around-the-clock blood levels of buprenorphine for six months following a single procedure. The ProNeura technology has the potential to be used in developing products for treating other chronic conditions such as Parkinson’s disease and hypothyroidism, where maintaining consistent, around-the-clock blood levels of medication may benefit the patient and improve medical outcomes.

 

Robust Pipeline:

Quarterly Financial Results (in, thousands):

Revenue: For the three months ended June 30, 2018, Titan reported approximately $2.7 million in revenue, compared with approximately $77,000 in the same period in 2017.  Revenues for the second quarter of 2018 reflect approximately $0.5 million related to the amortization of deferred revenue related to the sale to L. Molteni & C. Dei Frattelli Alitti Società Di Esercizio S.P.A. (“Molteni”) of the European intellectual property rights to Probuphine in March 2018, $7,000 related to the recognition of royalties earned on net sales of Probuphine by Braeburn prior to the termination of the Braeburn license, approximately $2.1 million related to terms of the license termination agreement, and $75,000 generated from Titan’s own sales of Probuphine after the return of the Braeburn license.  Revenue for the 2017 period reflects the recognition of royalties earned on net sales of Probuphine by Braeburn.

Profitability: Net loss applicable to common shareholders in the second quarter of 2018 was approximately $0.9 million, or approximately $0.04 per share, compared with a net loss applicable to common shareholders of approximately $3.5 million, or approximately $0.16 per share, in the same quarter in 2017.

Liquidity and financial flexibility: Cash Position as at June 30, 2018, Titan had cash of approximately $1.6 million. Also, the company recently priced its public offering with expected total gross proceeds of $9.5M.

 

Key risk factors and potential stock drivers:

• Successful commercialization of Probuphine would lead future direction for the company. Any adversities related to this might adversely impact the overall investor sentiments.
• TTNP is still an early stage entity and has not yet generated meaningful revenue and will likely operate at a loss as it grows its market position and seeks ways to monetize it.
• The company is offering several new convertible securities, which would have the potential dilution risk for the existing shareholders.
• TTNP has a history of operating losses. Therefore, any time or cost overrun in its ongoing R&D activities and its impact on business & financial profile will remain a key business sensitivity factor.

 

Stock Performance

 

Comments:

• On Friday, Oct 12th, 2018, TTNP closed at $0.2011, with a robust average volume of 2.5 million shares exchanging hands. Market capitalization is $5.44 million. The current RSI is 20.49
• At $0.2011, shares of TTNP are trading below its 50-day moving average (MA) at $0.57 and below its 200-day moving average (MA) at $0.91
• The present support and resistance levels for the stock are at $0.19 & $0.23 respectively.

 

 

Disclaimer

Traders News Source is a wholly owned subsidiary of Traders News Source LLC, herein referred to as TNS LLC.

Traders News Source has not been compensated for this report by anyone and the opinions if any are that of the author Vikas Agrawal, CFA. Author’s Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I, wrote this article myself, and it expresses my own opinions. I have no business relationship with any company whose stock is mentioned in the article.

This web site, published by TNS LLC, and is an investment newsletter that is built on the premise of assisting individual investors in learning about investing. Our goal as publishers of financial information is to provide research and analysis of investments to our subscribers. TNS LLC does not give buy or sell recommendations. We do purchase distribution rights from analyst, financial writers and bloggers for a fee that may be licensed to issue price targets and recommendations. Furthermore, we encourage you to speak to a licensed professional prior to making an investment in any type of publicly traded security.

We do sell advertising to other companies including brokerage firms, web sites, publicly traded issuers, investor relations firms, and investment publications, among others. TNS LLC makes no warranty as to the policies of these organizations, and in no way endorses their offers, services, or the content of their advertisements.

When an advertiser is a publicly traded company or a third party acting on behalf of a public company, we fully disclose all compensation in the email advertisement. Such disclosure is included in a disclosure statement in each of the advertisements sent via email.

17B Disclosure

Our reports/releases are a commercial advertisement and are for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our services, joining our site or our email/blog list as well as any social networking platforms we may use.

PLEASE NOTE WELL: TNS LLC and its employees are not a Registered Investment Advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever.

Release of Liability: Through use of this website viewing or using you agree to hold TNS LLC, its operator’s owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. TNS LLC encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled or is available from public sources and TNS LLC makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provide herein. Instead TNS LLC strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D.

TNS LLC is compliant with the Can Spam Act of 2003. TNS LLC does not offer such advice or analysis, and TNS LLC further urges you to consult your own independent tax, business, financial and investment advisors. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor’s investment may be lost or impaired due to the speculative nature of the companies profiled.

The Private Securities Litigation Reform Act of 1995 provides investors a ‘safe harbor’ in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be “forward looking statements”. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as “projects”, “foresee”, “expects”, “will”, “anticipates”, “estimates”, “believes”, “understands”, or that by statements indicating certain actions & quote; “may”, “could”, or “might” occur.

Understand there is no guarantee past performance will be indicative of future results. In preparing this publication, TNS LLC has relied upon information supplied by its customers, publicly available information and press releases which it believes to be reliable; however, such reliability cannot be guaranteed. Investors should not rely on the information contained in this website. Rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. The advertisements in this website are believed to be reliable, however, TNS LLC and its owners, affiliates, subsidiaries, officers, directors, representatives and agents disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of materials facts from such advertisement. TNS LLC is not responsible for any claims made by the companies advertised herein, nor is TNS LLC responsible for any other promotional firm, its program or its structure.